i-Biomarker™ CADX stands out with its unique approach, leveraging Generative and Explainable AI, Machine Learning, and Deep Learning for noninvasive cancer diagnosis. Analyzing circulating miRNA, NGS, Nanostring, or PCR data achieves unmatched accuracy in early detection, setting a new standard in the industry. Our advanced AI platform, i-Biomarker™ forms the foundation of our innovative and efficient diagnostic service. With an accuracy of 99-100%, our solution offers early diagnosis and screening for multiple cancer types, significantly enhancing treatment efficacy, improving patient survival rates, and reducing healthcare expenses. This underscores the profound impact of your work on patient care and outcomes.

Our Biomedical Data Science Services are meticulously tailored to your specific research needs. We leverage the latest bioinformatics, AI, machine learning methods, and deep biological expertise to provide custom solutions. This ensures that your unique research questions are addressed, fostering a sense of value and importance in your work.

            Our commitment is to redefine early cancer detection by harnessing the power of advanced AI, including Generative and Explainable AI, as well as Machine Learning and Deep Learning, to achieve breakthroughs in early cancer detection and empower biomedical research. We are dedicated to saving and enhancing lives through accurate diagnostics and enabling biomedical professionals to effortlessly derive actionable insights from complex data. Our dual approach integrates innovative cancer tests and comprehensive data science services to elevate patient care and streamline research, ensuring our diagnostics and AI platforms are revolutionary, transparent, and trustworthy for physicians. 

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 835911